Apart from the above conditions, MDSCs have been proven to decrease the efficacy of PD‐L1 blockade in many kinds of cancers, including lung cancer, pancreatic cancer, and melanoma, highlighting the potential of targeting MDSCs for reversing resistance to immunotherapy.251, 252, 253. Here, CD274 is linked to melanoma.